CNX is a member of the Standard & Poor’s Midcap 400 Index. In other recent news, CNX Resources Corporation reported fourth-quarter 2025 earnings that significantly surpassed market expectations. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min There is no expiration date on ...
Management confirmed that the company's flat production outlook aligns with a capital allocation strategy front-loaded in the first half, enabling potential flexibility to adjust activity if market ...
CNX Resources beat estimated earnings by 86.0%, reporting an EPS of $0.67 versus an estimate of $0.36. Revenue was up $33.00 million from the same period last year. Last quarter the company beat on ...
PITTSBURGH, Jan. 29, 2026 /PRNewswire/ -- CNX Resources Corporation (NYSE: CNX) ("CNX" or "the company") today released financial and operational results for the fourth quarter of 2025 by posting ...
4 analysts have expressed a variety of opinions on CNX Resources (NYSE:CNX) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Alan Shepard climbed from chief ...
Hosted on MSN
CNX Resources completes convertible notes exchange
CNX Resources ( (CNX)) has shared an announcement. On December 17, 2025, CNX Resources, a company in the energy sector, completed an exchange agreement involving approximately $122.1 million of its ...
Jazz Pharmaceuticals is the seller Inflexion acquired CNX in 2021 CNX is a London-based specialty pharmaceutical company Inflexion portfolio company CNX Therapeutics has acquired Jazz ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results